IMRX
Immuneering Corp
NASDAQ · Healthcare · Biotechnology · US
$3.82
−5.10%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$4.06
From 52W high−54.20%
Volume726666.00
Market cap$247.07M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 30, 2026
Open
$4.06
From 52W high
−54.20%
Volume
726666.00
Market cap
$247.07M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
P/E (TTM)
—
RSI (14)
46.5
MomentumView details →
1D Return
−5.10%
YTD Return
−41.49%
SummaryUpdated Sep 1, 2026
Immuneering Corporation (NASDAQ:IMRX) is a clinical-stage biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts. Originally a subsidiary of Teva Pharmaceutical Industries, the company went public in July 2021. Immuneering focuses on developing novel cancer treatments that target specific cellular pathways involved in tumor growth, particularly the RAS/RAF/MEK pathway which is commonly mutated in various cancers.
Similar companies
Latest newsMore news →
Immuneering reported third-quarter 2026 financial results for the quarter ended September 30, 2026.23h agoImmuneering said follow-up in its Phase 2 first-line pancreatic cancer trial is being extended because patients are living longer than projected.23h agoImmuneering presented data at the 2026 AACR Conference on pancreatic cancer supporting the mechanisms of atebimetinib designed to extend survival in pancreatic cancer.32d ago